NIH confirms cut-back in Indian trials but large sponsors hope for reform
This article was originally published in Scrip
Executive Summary
In what is probably one of its more lucid responses on the scrapping of a large number of clinical studies in India, the US National Institutes of Health (NIH), the largest source of funding for medical research in the world, has said that the Indian trials were stopped mainly because of the country's evolving trial regulations.
You may also be interested in...
Industry Sponsored Trials Fall Sharply In Challenging Indian Environment
A rise in bureaucracy and increased liability for clinical trial sponsors have impacted the popularity of India as a location for pharmaceutical companies’ clinical studies. Trialtrove’s Deborah Jeanfavre examines the data, which show a continuing decrease in new industry-sponsored trials starting in India over the past five years.
High Stakes: Boehringer Faces Pre-Expiry India Jardiance Challenge
Indian firms debut empagliflozin copies ahead of expected patent expiry for diabetes blockbuster Jardiance in the country. Spotlight now on how swiftly Boehringer Ingelheim can fend off the entrants and whether the local challenge goes well beyond “inspiration” from the goings-on in the case of another SGLT2 inhibitor dapagliflozin.
CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.